Cat. No. 1396
Alternative Name: 4-HPR
Chemical Name: N-(4-Hydroxyphenyl)retinamide
Biological ActivitySynthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Le Doze et al (2000) Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab.Dispos. 28 205. PMID: 10640519.
Takahashi (2000) Antioxidant properties of N-(4-hydroxyphenyl)retinamide (fenretinide). Biol.Pharm.Bull. 23 222. PMID: 10706389.
Ulukaya and Wood (1999) Fenretinide and its relation to cancer. Cancer Treat.Rev. 25 229. PMID: 10448131.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Fenretinide include:
Johansson et al (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 4 2175. PMID: 23868472.
Do you know of a great paper that uses Fenretinide from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Fenretinide, supplier, Synthetic, retinoid, agonists, Potent, anti-cancer, agent, RXR, Retinoid, X, Receptors, RAR, RAMBA, Retinoic, Acid, Tocris Bioscience, Retinoic Acid Receptor products
Find multiple products by catalog number
New Products in this Area
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activatorBexarotene
Potent and selective RXR agonistGSK 2033
Potent LXR antagonist27-Hydroxycholesterol
LXR agonist; also ER partial agonistDY 268
Potent FXR antagonistCytosporone B
High affinity Nur77 agonist
July 29 - 31, 2016